1. Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines
- Author
-
Christopher R. M. Asquith, Christoph Grundner, William J. Zuercher, Chad Torrice, Neil Fleck, and Daniel J. Crona
- Subjects
Clinical Biochemistry ,Antitubercular Agents ,Pharmaceutical Science ,Microbial Sensitivity Tests ,01 natural sciences ,Biochemistry ,Article ,Mycobacterium tuberculosis ,Structure-Activity Relationship ,chemistry.chemical_compound ,Aniline ,Drug Discovery ,Quinazoline ,Potency ,Anti tubercular ,Molecular Biology ,Aniline Compounds ,Dose-Response Relationship, Drug ,Molecular Structure ,biology ,010405 organic chemistry ,Organic Chemistry ,Quinoline ,biology.organism_classification ,Combinatorial chemistry ,0104 chemical sciences ,3. Good health ,010404 medicinal & biomolecular chemistry ,chemistry ,Quinazolines ,Quinolines ,Molecular Medicine - Abstract
We screened a series of 4-anilinoquinolines and 4-anilinoquinazolines and identified novel inhibitors of Mycobacterium tuberculosis (Mtb). The focused 4-anilinoquinoline/quinazoline scaffold arrays yielded compounds with high potency and the identification of 6,7-dimethoxy-N-(4-((4-methylbenzyl)oxy)phenyl)quinolin-4-amine (34) with an MIC90 value of 0.63–1.25 µM. We also defined a series of key structural features, including the benzyloxy aniline and the 6,7-dimethoxy quinoline ring, that are important for Mtb inhibition. Importantly the compounds showed very limited toxicity and scope for further improvement by iterative medicinal chemistry.
- Published
- 2019
- Full Text
- View/download PDF